- Design
- Systematic review and meta-analysis of 19 mostly uncontrolled studies
- Population
- 445 patients with relapsing or refractory lupus nephritis receiving rituximab
- Primary outcome
- Complete, partial and overall renal response at 6, 12 and 24 months
- Effect
- Complete response 33% (6 months), 41% (12 months), 42% (24 months); overall response 66–70%
This meta-analysis pooled 19 studies with 445 patients with relapsing or refractory lupus nephritis treated with rituximab as rescue or add-on therapy.
Complete renal response was 33% at 6 months, 41% at 12 months and 42% at 24 months. Overall response, complete or partial, was about two-thirds at each time point. Proteinuria fell by about 2.7 g/day and serum creatinine by about 12 µmol/L. No publication bias was detected.
Rituximab is widely used off-label in this setting, and these numbers give clinicians a realistic expectation to share with patients. But almost all the studies were uncontrolled, so the response rates cannot be attributed to rituximab alone: patients also received other immunosuppression, and some refractory disease improves with time. Large randomised trials of rituximab in lupus nephritis have not shown clear benefit as first-line add-on, and newer anti-CD20 and other agents are now part of the picture. Rituximab use for lupus nephritis is off-label in India as elsewhere.
- Consider rituximab for relapsing or refractory lupus nephritis after standard therapy, discussing realistic response rates.
- Expect complete response in about a third at 6 months and two in five by a year in this setting.
- Screen for hepatitis B and check immunoglobulins before giving rituximab.
- Confirm adherence and repeat biopsy where appropriate before labelling disease refractory.
- Record that rituximab is off-label for lupus nephritis and document consent.
Why it matters
It gives a pooled benchmark for an off-label treatment that many nephrologists already use.
Don't overread it
The studies were mostly uncontrolled, so the response rates cannot be credited to rituximab alone.
The statistics, in plain English
A pooled complete response of 0.41 (95% CI 0.28–0.54) at 12 months means between about a quarter and a half of patients would be expected to respond completely. Without control groups, this describes what happened, not what rituximab added.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for nephrology, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free